lysosomal storage disorder News
-
Gain Therapeutics Outlines Key Objectives For 2022 Following Its Inaugural R&D Day
BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today held its inaugural research and development day webinar. ...
-
Gain Therapeutics Presents Preclinical Data On Its Structurally Targeted Allosteric Regulators In GBA1 Gaucher Disease At The WORLDSymposium 2022
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functions BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric ...
-
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated Based on these data, Sangamo has initiated Phase 3 planning The fifth patient was recently dosed, in the third dose cohort Q3 ...
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
-
Gain Therapeutics Announces Additional Details On Its February 4th Virtual R&D Day
Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you